Cited by 26Bone health and osteoporosis researchVitamin D Research StudiesBone health and treatments

Between-meal risedronate does not alter bone turnover in nursing home residents

Open access
Agrawal, Sabina, Krueger, Diane C., Engelke, Jean A., Nest, Lori J., Krause, Peggy F., Drinka, Paul J., Binkley, Neil C.·2006·Journal of the American Geriatrics Society

Abstract

OBJECTIVES: To assess the effect of between‐meal weekly risedronate and daily calcium 630 mg and vitamin D 400 IU on bone turnover markers. DESIGN: Randomized,double‐blind,placebo‐controlled trial. SETTING: Skilled nursing home (NH). PARTICIPANTS: Sixty skilled‐NH residents (46 men, 14 women), mean age±standard deviation of 76±6, were randomized to receive risedronate 30 mg (n=31) or matching placebo (n=29) once weekly for 12 weeks. All received 315 mg calcium with 200 IU vitamin D twice daily. MEASUREMENTS: Bone‐specific alkaline phosphatase (BSAP), N‐telopeptide of type 1 collagen (NTx), 25‐hydroxyvitamin D (25OHD), and parathyroid hormone were measured at baseline and 6 and 12 weeks. RESULTS: Risedronate reduced BSAP significantly more than placebo ( P <.05) at 6 weeks but not at 12 weeks; no treatment effect on serum NTx was observed. Defining hypovitaminosis D as a serum 25OHD concentration below 32 ng/mL, 50 of 53 (94%) study participants were low at baseline (mean 25OHD 19 ng/mL). Vitamin D levels remained insufficient in 74% of participants after 12 weeks. CONCLUSION: In this NH population, weekly risedronate administered using a between‐meal dosing schedule reduced serum BSAP at 6 weeks of treatment; this effect was not observed at 12 weeks. The overall lack of change in bone turnover markers suggests that this risedronate dose and schedule would not be expected to increase bone density or reduce fracture risk in this population. Hypovitaminosis D was common and not reliably corrected by 400 IU of vitamin D daily. Despite an extremely high osteoporotic fracture risk in NH residents, additional study is required to determine under which conditions pharmacological treatment is efficacious in this population and define approaches that assure vitamin D repletion.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1532-5415.2006.00696.x

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 13

  1. Gabrel CS. Characteristics of elderly nursing home current residents and dis- charges: Data from the 1997 National Nursing Home Survey. Adv Data 2000;312:1-15.
  2. Reginster JY, Deroisy R, Pirenne H et al. High prevalence of low femoral bone mineral density in elderly women living in nursing homes or community- dwelling: A plausible role of increased parathyroid hormone secretion. Os- teoporos Int 1999;9:121-128.
  3. Kane RS, Burns EA, Goodwin JS. Minimal trauma fractures in older nursing home residents: The interaction of functional status, trauma and site of frac- ture. J Am Geriatr Soc 1995;43:156-159.
  4. Greenspan SL, Myers ER, Kiel DP et al. Fall direction, bone mineral density, and function: Risk factors for hip fracture in frail nursing home elderly. Am J Med 1998;104:539-545.
  5. Elliott ME, Binkley NC, Carnes M et al. Fracture risks for women in long-term care: High prevalence of calcaneal osteoporosis and hypovitaminosis D. Phar- macotherapy 2003;23:702-710.
  6. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the eld- erly: Consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001;22:477-501.
  7. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC et al. Effect of vitamin D on falls: A meta-analysis. JAMA 2004;291:1999-2006.
  8. Kanis JA, Johnell O, Oden A et al. Intervention thresholds for osteoporosis in men and women: A study based on data from Sweden. Osteoporos Int 2005; 16:6-14.
  9. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-1352.
  10. Lin JH. Bisphosphonates: A review of their pharmacokinetic properties. Bone 1996;18:75-85.
  11. Stepan JJ, Burckardt P, Vaclav H. The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: The influence of vitamin D deficiency and hormonal status. Bone 2003;33:589-596.
  12. Bischoff HA, Stahelin HB, Dick W et al. Effects of vitamin D and calcium supplementation on falls: A randomized controlled trial. J Bone Miner Res 2003;18:343-351.
  13. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomized double blind controlled trial. BMJ 2003;326:469-474.

Cited by

Sorted by citations

Authors
Agrawal, S., Krueger, D. C., Engelke, J. A., Nest, L. J., Krause, P. F., Drinka, P. J., & Binkley, N. C.
Affiliations
University of Wisconsin–Madison (US)
Corresponding author
Agrawal, Sabina
Venue
Journal of the American Geriatrics Society
Publisher
Wiley
Published
2006-05
Volume
54
Issue
5
Pages
790-795
ISSN
  • 0002-8614 (ISSN-L)
  • 1532-5415
OpenAlex
W1573520461
Cited by
26
References
29
Citations by year
2021: 1 · 2019: 3 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 2 · 2013: 1 · 2012: 3
FWCI
3.06
Type
journal article
Language
en
Open access
Locations
  • Journal of the American Geriatrics Society (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Pfizer
  • Procter and Gamble
  • Eisai
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Vitamin D Research Studies
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
risedronate, bone turnover markers, nursing home residents, bone-specific alkaline phosphatase, N-telopeptide, vitamin D insufficiency, vitamin D deficiency, calcium supplementation, parathyroid hormone, osteoporosis, fracture risk, bisphosphonates
MeSH terms
Risedronic Acid, Aged, Alkaline Phosphatase, Calcium, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Male, Nursing Homes, Peptides, Etidronic Acid, Vitamin D, Bone Remodeling, Collagen Type I, Bone Density Conservation Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review